Mannkind Corp

NASDAQ: MNKD
$4.16
+$0.05 (+1.2%)
Closing price April 23, 2024
MannKind Corporation is a pioneering biopharmaceutical firm dedicated to creating inhaled therapeutic products for diabetes and rare lung diseases. Its flagship product, Afrezza, is an innovative inhaled insulin offering a new approach to glycemic control in adults. Additionally, MannKind is developing treatments for pulmonary arterial hypertension and other serious lung conditions. With strategic partnerships for global distribution and a commitment to advancing respiratory health, MannKind stands at the forefront of inhalation technology for medical treatments.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest in most...
The May 15 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Broadcom, Coca-Cola, Conagra Brands, Deere, Jumia Technologies, MannKind, Shopify, Take-Two Interactive Software, TJX...
The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The April 15 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 29 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
We screened our 24/7 Wall St. research database and found five biotech stocks trading under the $10 level that could provide investors with some solid upside potential.
The February 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The February 15 short interest data have been compared with the previous report, and short interest in...
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The January 31 short interest data have been compared with the previous report, and short interest in...
The January 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The December 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The December 14 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The November 30 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.